Medically reviewed by Andrew Greenberg, MD Bull’s-eye maculopathy is an eye problem that affects the macula, the part of the ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

March 7, 2025 – The FDA has approved a new gene therapy for macular telangiectasia type 2 (MacTel), a rare eye disease that causes vision loss. The approval marks the first and only ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ... human CNTF -- to the affected eye via a surgical intravitreal ...

Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia type 2 (MacTel), a rare eye disease leading to progressive and ...

The tiny eye insert delivers cell therapy to slow ... has approved its “encapsulated cell therapy” implant for Macular Telangiectasia Type 2, a disease known as MacTel. MacTel is a rare ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Revakinagene taroretcel-lwey is the first FDA-approved treatment for macular telangiectasia type 2 ... protein administration for chronic eye disease following surgical implantation.

Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.